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Abstract: The SARS-CoV-2 pandemic has created a public health crisis worldwide. Although vaccines
against the virus are efficiently being rolled out, they are proving to be ineffective against certain
emerging SARS-CoV-2 variants. The high degree of sequence similarity between SARS-CoV-2 and
other human coronaviruses (HCoV) presents the opportunity for designing vaccines that may offer
protection against SARS-CoV-2 and its emerging variants, with cross-protection against other HCoVs.
In this study, we performed bioinformatics analyses to identify T and B cell epitopes originating
from spike, membrane, nucleocapsid, and envelope protein sequences found to be evolutionarily
conserved among seven major HCoVs. Evolutionary conservation of these epitopes indicates that
they may have critical roles in viral fitness and are, therefore, unlikely to mutate during viral
replication thus making such epitopes attractive candidates for a vaccine. Our designed vaccine
construct comprises of twelve T and six B cell epitopes that are conserved among HCoVs. The vaccine
is predicted to be soluble in water, stable, have a relatively long half-life, and exhibit low allergenicity
and toxicity. Our docking results showed that the vaccine forms stable complex with toll-like receptor
4, while the immune simulations predicted that the vaccine may elicit strong IgG, IgM, and cytotoxic
T cell responses. Therefore, from multiple perspectives, our multi-subunit vaccine design shows
the potential to elicit a strong immune-protective response against SARS-CoV-2 and its emerging
variants while carrying minimal risk for causing adverse effects.
Keywords: human coronaviruses; MERS; SARS-CoV-2; SARS-CoV; epitope; vaccine
1. Introduction
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused
a worldwide pandemic that continues to negatively impact the global economy, social
dynamics, and health care systems [1]. SARS-CoV-2 has been identified as the seventh
coronavirus that can infect humans [2]. Although coronaviruses have infected the human
population repeatedly over the past century [3], only a few have caused severe large-scale
outbreaks. Prior to SARS-CoV-2, the SARS-CoV outbreak occurred in southern China in
November 2002, followed by the Middle East respiratory syndrome (MERS-CoV) outbreak
in Saudi Arabia and South Korea, respectively, in 2012 and 2015. SARS-CoV and MERS-
CoV have an estimated mortality rate of ~9.6% and 35%, respectively [4,5]. Moreover, four
other human coronaviruses (HCoVs) associated with mild upper respiratory symptoms,
have previously been identified, i.e., HCoV-NL63, HCoV-229E, HCoV-OC43, and HCoV-
HKU1 [6–8].
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The genomes of SARS-CoV and MERS-CoV are, respectively, 79% and 50% similar
to SARS-CoV-2 [9]. Out of these HCoVs, SARS-CoV and SARS-CoV-2 not only share
a phylogenetic relationship, but also exhibit a high level of similarity in the cell entry
mechanism and the use of human cell receptors [10,11].
The urgency for having an effective vaccine against SARS-CoV-2 has given rise to
fervent efforts toward vaccine design worldwide [12,13]. Over 200 candidate vaccines have
been developed, and several of them are currently authorized for use in different parts of the
world and have shown varying efficacy [14]. Two mRNA-based vaccines, BNT162b2 (Pfizer–
BioNTech, New York, NY, USA and Mainz, Rhineland-Palatinate, Germany), mRNA-1273
(Moderna, Cambridge, MA, USA), showed up to 95% efficacy, the adenovirus vector-based
Ad26.CoV2.S (Johnson & Johnson, New Brunswick, NJ, USA) presented 72% efficacy
in the USA but 57% in South Africa, while the chimpanzee adenovirus vector-based
ChAdOx (AZD1222) (AstraZeneca, Cambridge, UK) presented 70% efficacy. Similarly,
heterologous recombinant adenovirus vector-base Gam-COVID-Vac (Sputnik V, Moscow,
Russia) demonstrated 91% efficacy in the preliminary phase 3 trials, while the protein-
based vaccine NVX-CoV237 (Novavax, Gaithersburg, MD, USA) was 89% efficient in
the U.K. but 49% in South Africa [14–18]. Two inactivated virus vaccines, CoronoVac
(Sinovac, Beijing, China) and BBIBP-CorV (Sinopharm, China National Pharmaceutical
Group, Beijing, China), passed through phase 3 clinical trials and were reported to show
from 50% to 91% efficacy. The data, however, were not published at the time of writing
of this manuscript. In all of the vaccines that have been designed so far, the antigenic
target used was the spike protein, which is the most antigenic, highly variable, and prone
to mutations [19,20]. Due to a high substitution/mutation rate and rapid transmissions,
new variants of SARS-CoV-2 have been continuously emerging globally, posing threats
to circumvent the efficacy of current vaccines, possibly leading to a novel-SARS-CoV-2-
variant-assciated surge in transmissions [15]. In fact, there have already been reports of
the current vaccines losing effectiveness against the emerging SARS-CoV-2 variants [21,22].
Therefore, vaccines that can stay effective against the emerging strains while simultaneously
exhibiting an acceptable safety profile are the need of the hour.
One possible way to design such vaccines is to include epitopes, aside from spike,
from SARS-CoV-2 that are evolutionary conserved. Structural proteins of coronaviruses,
including spike (S), envelope (E), membrane (M), and nucleocapsid (N), have been shown
to elicit greater immunogenicity compared to those against the non-structural proteins [23].
A vaccine bearing a design that is based on conserved epitopes of structural proteins is
likely to remain effective against emerging variants since mutations in conserved regions,
as they incur a fitness cost to the virus, are not likely to occur. Corroborating that argument
are several studies showing that individuals with previous exposure to other HCoVs
exhibit high protection against SARS-CoV-2 [24], indicating that due to their functional
significance, certain antigenic regions have remained conserved in all HCoVs.
In this study, using in silico analyses, we designed a multi-subunit chimeric SARS-
CoV-2 vaccine comprising of CD8+ T and linear B cell epitopes originating from the regions
of envelope (E), membrane (M), nucleocapsid (N), and spike (S) proteins found to be
conserved among several human coronaviruses. Evolutionary conservation of these motifs
implies their critical roles in viral fitness, indicating that they are unlikely to become
mutated during viral replication, making them attractive candidates for a SARS-CoV-2
subunit vaccine that promises to provide coverage against multiple HCoVs, including
SARS-CoV-2 and its emerging variants.
2. Materials and Methods
2.1. Nucleotide Sequence Retrieval and Phylogenetic Analysis
In the first step, we used E, N, M, and S reference sequences for all seven HCoVs,
available at the NCBI Genbank database, namely, SARS-CoV-2 (NC_045512), SARS-CoV
(NC_004718), MERS-CoV (NC_019843), HCoV-NL63 (NC_005831), HCoV-229E (NC_002645),
HCoV-HKU1 (NC_006577), and HCoV-OC43 (NC_006213) to retrieve nucleotide sequences
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for each HCoV exhibiting >90% sequence similarity to the reference sequences. The re-
trieved sequences were aligned using the online MAFFT alignment tool (https://mafft.cbrc.
jp/alignment/server/ (accessed on 23 May 2020)). In order to analyze the evolutionary
relationship between SARS-CoV-2 with other HCoVs (SARS-CoV, MERS-CoV, HCoV-NL63,
HCoV-229E, HCoV-OC43, and HKU-1), nucleotide alignment was used to construct a
maximum-likelihood (ML) phylogenetic tree using IQ-TREE v1.6.12 [25]. The ML tree was
constructed using the general time reversible (GTR) model of nucleotide substitution and
gamma correction for among site rate variation. The ultrafast bootstrap method was used
with 1000 replicates to infer support branching in the tree topology. The Newick file for the
ML tree was visualized using FigTree v1.4.4.
2.2. Protein Sequence Retrieval and Vaccine Design Workflow
In the next step, E, N, M, and S reference sequences for all seven HCoVs (described
above) were used in BLAST search (pBLAST), with filters of 90–100% percent identity and
100% query coverage, to retrieve E, N, M, and S protein sequences from HCoVs that are
over 90% conserved. The total number of protein sequences from each HCoV used in our
study are shown in Table 1.
Table 1. Number of protein sequences for envelope, membrane, nucleocapsid, and spike proteins
from HCoVs. The table shows the number of sequences used in our study that gave 100% query
coverage and >90% conservation between HCoVs.
HCoVs
Protein Sequences
Envelope Membrane Nucleocapsid Spike
HCoV-NL63 2 11 36 51
HCoV-229E 5 6 51 71
HCoV-OC43 6 15 106 183
HCoV-HKU1 3 8 28 26
MERS-Cov 18 35 87 250
SARS-CoV 13 23 29 80
SARS-CoV-2 56 176 3082 1139
Subsequently, the E, N, M, and S protein sequences for each HCoV were sepa-
rately aligned using an online MAFFT alignment tool [26], and each alignment was used
to generate protein specific consensus sequences for each HCoV with the Consensus
Maker tool (https://www.hiv.lanl.gov/content/sequence/CONSENSUS/SimpCon.html
(accessed on 25 May 2020)). In the next step, protein-specific consensus sequences from the
HCoVs were aligned again, and the conserved regions within the E, N, M, and S proteins
from the seven HCoVs were identified using ESPript 3.x [27] and Jalview 2.11.1.3 [28]
software. Additionally, to take into account the recently emerging mutations among
SARS-CoV-2 variants, approximately 5000 whole genome sequences of three SARS-CoV-
2 variants:B.1.1.7 (VOC-202012/01) identified in the U.K., 501Y.V2 (B.1.351) identified
in the South Africa, and 501Y.V3 (P.1) identified in Brazil were retrieved from GSAID
(https://www.gisaid.org/ (accessed on 5 April 2021), and aligned with MAFFT to gen-
erate consensus sequences for each of the variants using BioEdit [29]. Nucleotide con-
sensus sequences were then translated into amino acid sequences using the Expasy tool
(https://web.expasy.org/translate/ (accessed on 5 April 2021)). The resulting amino acid
sequences were trimmed with reference to E, N, M, and S reference protein sequences in
Aliview [30]. The protein-specific consensus sequences for each HCoV, including the SARS-
CoV-2 variants, were used to predict B and T cell epitopes and to design a multi-subunit
vaccine based on the selected epitopes as described below (Figure 1).
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Figure 1. Vaccine design workflow.
2.3. In Silico CD8+ T Cell and B Cell Epitope Mapping, and Epitope Conservation Analysis
Using E, N, M, and S protein consensus sequences, HCoV-derived cytotoxic T cell
epitopes were predicted using the web-based CTLPred tool [31] and a combined support
vector machine and artificial neural network approach. Human leukocyte antigen (HLA)
restriction was identified using the nHLAPred tool for each predicted T cell epitope [32].
The prediction of linear B cell epitopes was performed using the web-based ABCpred
tool [33]. Epitopes located in the conserved regions between the 7 HCoVs or 3 closely
related viruses, namely, SARS-CoV-2, SARS-CoV, and MERS-CoV, were selected. Predicted
CD8+ T and B cell epitopes were compared to the experimentally validated SARS-CoV epi-
topes available in IEDB (http://www.iedb.org/ (accessed on 10 April 2021)) database [34]
and that had been reported by other studies.
2.4. Selection of Immunogenic and Non-Toxic Epitopes for Multi-Subunit Vaccine Design
The predicted epitopes were shortlisted after screening for immunogenicity and
toxicity. VaxiJen v2.0 [35] was used to evaluate immunogenicity (a score >0.4 (default
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value) was considered as antigenic), while ToxinPred [36] was used to evaluate the toxicity
of the epitopes. Epitopes predicted to be immunogenic and non-toxic were selected to
design the multi-subunit vaccine.
2.5. Design of a Multi-Subunit Vaccine
As indicated earlier, the conserved epitopes predicted to be immunogenic and non-
toxic were used to design a multi-subunit vaccine (Supplementary Figure S1). For the
vaccine design, the CD8+ T cell epitopes were linked using an AAY linker, and linear B
cell epitopes were linked by an GPGPG linker [37]. At the C-terminal of the vaccine, a
six-histidine tail was added while at the N-terminus, β-defensin amino acid sequence
(UniProt ID: Q5U7J2) was added to the first epitope via an EAAAK linker. β-defensin acts
as an adjuvant and mediates recruitment of naïve T cells and immature dendritic cells at
the site of infection/immune activity [38].
2.6. Evaluation of Physico-Chemical Properties, and Allergenicity Profile of the
Multi-Subunit Vaccine
Physico-chemical properties, such as half-life, instability index, aliphatic index, and
grand average of hydrophobicity of the vaccine were determined using the ProtParam
server (http://web.expasy.org/protparam (accessed on April 12 2021)), while the basic
property of allergenicity of the multi-subunit vaccine was assessed using AllerTOP v. 2.0
server [39]. The immunogenicity/antigenicity of the multi-subunit vaccine was evaluated
using the VaxiJen v2.0 server [35].
2.7. Prediction and Refinement of Secondary and 3D Structures
The secondary structure of the designed vaccine was predicted using the PSIPRED
server [40], while the 3D structure was predicted using both the I-TASSER [41] and the
Phyre2 server (using an intensive modelling approach) [42]. The best model was selected
and refined/optimized using the Galaxyrefine server [43], while PROSA [44] and Ra-
machandran plot analyses were performed to analyze the quality of the refined structure.
Solubility of the protein (vaccine) was determined using the Protein-Sol server [45].
2.8. Molecular Docking Analysis
Since Toll-like receptor 4 (TLR4) is capable of recognizing various exogenous and
endogenous ligands such as viral protein, lipopolysaccharide, heat shock proteins, β-
defensin, etc., which leads to dendritic cell maturation, and up-regulation of costimulatory
molecules resulting in type 1 polarized adaptive immune response [46,47], we performed
molecular docking between TLR4 and our vaccine-construct (containing β-defensin as
an adjuvant). For molecular docking calculations, the crystal structure of the human
TLR4 deposited in the Protein Data Bank with the PDB accession code of 4G8A [48] was
retrieved and utilized as a template. For the preparation of the TLR4 crystal structure,
all crystallographic water molecules and heteroatoms were removed. Moreover, mutated
residues were reversed and refined. The protonation state of the TLR4 was then examined,
and hydrogen atoms were consequently added [49]. Binding modes of the developed
vaccine with the human TLR4 were then predicted using the PatchDock server [50]. All
predicted docked complexes (exactly 1000 solutions) were then refined and rescored using
the FireDock server [51,52]. The interactions between the vaccine and the TLR4 were
resolved using the LigPlot + software [53].
2.9. In Silico Simulation of the Immune Response
The humoral and cellular immune response against the multi-subunit vaccine con-
struct was simulated using the C-ImmSim tool [54]. For simulations, the following pa-
rameters were used: three injections at 4-week intervals; simulation steps = 1000; time to
simulation = default; injection volume = vaccine only and no LPS. Additionally, we used
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NetCTL [55] and NetChop [56,57] to predict proteasomal sites (using default a value of 0.5)
and the possible proteolytic release of the epitopes from the vaccine construct.
3. Results
3.1. Phylogenetic and Sequence Similarity among the Human Coronaviruses
To evaluate the genetic similarity among the seven human coronaviruses, we con-
structed ML phylogenetic trees that revealed alpha-HCoVs, NL63 and 229E, clustered
distantly from Beta-HCoVs, OC43 and HKU1. Importantly, SARS-CoV-2, SARS-CoV, and
MERS-CoV clustered together, indicating a close phylogenetic relatedness between these
viruses (Supplementary Figure S2).
In the next step, we identified conserved regions in the consensus sequences of the
E, N, M, and S proteins from seven HCoVs (Figure 2A and Supplementary Figure S3)
and three phylogenetically closely related HCoVs-SARS-CoV-2, SARS-CoV, and MERS-
CoV (Figure 2B and Supplementary Figure S4) using ESPript 3.x and Jalview 2.11.1.3
software [28]. The results revealed several regions within N, M, and S proteins exhibiting
more than 40% homology among the seven HCoVs, while no conserved regions were found
for the E protein (Supplementary Figure S3), corroborating the findings of the phylogenetic
analysis. Additionally, while the conservation was analyzed for SARS-CoV-2, SARS-CoV,
and MERS-CoV, the results showed greater sequence conservation for E, N, M, and S
compared to those in the seven hCoVs (Supplementary Figures S3 and S4).
In the next steps, focusing on these conserved regions, we predicted CD8+ T and B
cell epitopes for each SARS-CoV-2 protein.
3.2. CD8+ T Cell Epitopes Originating in Conserved Regions of E, N, M, and S Proteins
CD8+ T cell epitopes were analyzed for E, N, M, and S proteins, focusing on the
conserved regions of the seven HCoVs protein sequences.
No CD8+ T cell epitopes were identified in the conserved regions of E protein among
all seven HCoVs (Supplementary Figure S3 and Table 2). However, when the analysis
was carried out using E sequences from only SARS-CoV-2, SARS-CoV and MERS-CoV,
two conserved CD8+ T cell epitopes were identified, each exhibiting ~44% and ~77%
conservation (Table 3 and Supplementary Figure S4). These epitopes were found to be
restricted by HLA- C*0401 HLA-A*0205, HLA-A*0301, HLA-A2, HLA-A3, and HLA-B*5301
(Table 3). Similarly, analysis of the M protein sequences showed the presence of one CD8+
T cell epitope with ~55% conservation among all seven HCoVs (Table 2), which was found
to be restricted by HLA-A24, HLA-A*2402, and HLA-Cw*0401 (Table 2). Conservation
of this epitope between SARS-CoV-2, SARS-CoV, and MERS-CoV was found to be 66%
(Table 2 and Supplementary Figure S4).
Further analysis of SARS-CoV-2, SARS-CoV, and MERS-CoV epitopes revealed three
conserved CD8+ T cell epitopes exhibiting ~44%, ~66%, and ~88% conservation between
the three viruses (Table 3 and Supplementary Figure S4). These epitopes were found to be
restricted by HLA-C*0401 and then by HLA -A*0203, -A*24, -B*2703, and -B*35 (Table 3).
Analysis of the N protein sequences showed one CD8+ T cell epitope with 44%
conservation among all HCoVs (Table 2 and Supplementary Figure S3). This epitope
was found to be restricted by HLA-Cw*0401, HLA-A*0202, HLA-A*0203, HLA-A*0205,
HLA-A*0301, HLA-A*0401, HLA-B*35, and HLA-B*3501 (Table 2). Again, conservation of
this epitope was increased to ~77% when the analysis was focused only on SARS-CoV-2,
SARS-CoV, and MERS-CoV (Table 3 and Supplementary Figure S4). Seven additional
conserved CD8+ T cell epitopes were identified for the N protein with ~77%, ~66%, and
~55% conservation (Table 3 and Supplementary Figure S4). Most of the conserved epitopes
were found to be restricted by HLA- C*0401 and then by HLA-A*0201, HLA-A*2402,
HLA-A*A2, HLA-A*6801, HLA-B*3501, HLA-B*51, and HLA-B*5301 (Table 3).
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Figure 2. Cont.
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Figure 2. Conservation of envelope (E), membrane (M), nucleocapsid (N), and spike (S) protein sequences in seven HCoVs
and in SARS-CoV-2, SARS-CoV, and MERS-CoV. Conservation of E, M, N, and S proteins in (A) seven HCoVs and (B) SARS-
CoV-2 (COV2), SARS-CoV (SARS), and MERS-CoV (MERS). Only the regions showing conservancy are presented for N and
S proteins (full length sequences are shown in Supplementary Figures). Images are shown from ESPript results. Conserved
regions are colored in red.
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Table 2. Predicted CD8+ T cell epitopes found to be conserved in the seven HCoVs. Conserved amino acids are shown in bold letters. HLA restriction for each epitope is also given.
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Table 3. Predicted CD8+ T cell epitopes found to be conserved SARS-CoV-2, SARS-CoV, and MERS-CoV. Conserved amino acids are shown in bold letters. HLA restriction for each epitope
is also given.
Conserved CD8 + T Cell Epitopes in SARS-CoV-2, SARS-CoV, and MERS-CoV
Envelope
№ SARS-CoV-2 HLA-resctriciton SARS-CoV HLA-resctriciton MERS-CoV HLA-resctriciton Conservation (%)
1 AILTALRLC HLA-Cw*0401 AILTALRLC HLA-Cw*0401 AFLTATRLC HLA-Cw*0401 77












1 SFNPETNIL HLA-A*0203,HLA-Cw*0401, SFNPETNIL
HLA-A*0203,HLA-
Cw*0401, SFNPETNCL HLA-Cw*0401 88
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NPNNNAATV HLA-B*5301,HLA-Cw*0401 NPNNDSAIV HLA-Cw*0401 55
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Unlike E, N, and M proteins, two conserved CD8+ T cell epitopes were found for the
S protein among all the HCoVs, with ~44% and ~66% conservation, respectively (Table 2
and Supplementary Figure S3). These epitopes were found to be mainly restricted by HLA-
C*0401, HLA-A*0206, and HLA-A*3301 (Table 2). Conservation of these two epitopes
increased to ~66% and ~77% in the SARS-CoV-2, SARS-CoV, and MERS-CoV sequences
(Table 3 and Supplementary Figure S4). Further analysis of epitopes in the S sequences
from these three HCoVs revealed 12 conserved CD8+ T cell epitopes, with ~44%, ~55%,
~66%, ~77%, and ~88% conservation (Table 3 and Supplementary Figure S4). Most of
the conserved epitopes were found to be restricted by HLA- C*0401, HLA-A1, HLA-A2,
HLA-A*0206, HLA-A24, HLA-A*2402, HLA-A*3301, HLA-A*6801, HLA-B*3501, HLA-B8,
HLA-B27, HLA-B*2706, and HLA-B51 (Table 3).
It is important to note that all CD8+ T epitopes predicted in the E, N, M, and S
sequences were found to be 100% conserved in the latest deposited 5000 SARS-CoV-2
sequences as well as in the three variants of SARS-CoV-2 (Supplementary Figure S5).
3.3. Predicted Linear B Cell Epitopes Found to Be Conserved in E, N, M, and S Protein Sequences
of HCoVs
E, N, M, and S consensus protein sequences of seven HCoVs were used to predict
linear B cell epitopes of varying length (between 10 to 20 amino acids). Even though the
protein sequences showed several regions exhibiting more than 40% homology among
the seven HCoVs, no B cell epitopes were found in the conserved regions. Analysis of
SARS-CoV-2, SARS-CoV, and MERS-CoV, however, revealed conserved B cell epitopes
among these three viruses. Two B cell epitopes, with ~42% and ~50% conservation, were
predicted for the E protein, while only one epitope, with ~86% conservation, was predicted
for the M protein (Table 4, Supplementary Figure S4). Similarly, for the N proteins, four
epitopes were found to be conserved in the N protein with ~50%, ~56%, and ~69%, while
five epitopes were found to be conserved in the S protein, showing ~50%, ~56%, and ~63%
conservation (Table 4, Supplementary Figure S4).
Table 4. Predicted B cell epitopes found to be conserved in E, N, M, and S protein sequences of SARS-CoV-2, SARS-CoV,
and MERS-CoV. Conserved amino acids are in bold letters.
Conserved B cell epitopes in SARS-CoV-2, SARS-CoV, and MERS-CoV
Envelope
№ SARS-CoV-2 SARS-CoV MERS-CoV Conservation (%)
1 YSFVSEETGTLIVN YSFVSEETGTLIVN LPFVQERIGLFIVN 50
2 YSFVSEETGTLI YSFVSEETGTLI LPFVQERIGLFI 42
Membrane
1 SMWSFNPETNILLN SMWSFNPETNILLN SWWSFNPETNCLLN 86
Nucleocapsid
1 TASWFTALTQHGKEDL TASWFTALTQHGKEEL TVSWYTGLTQHGKVPL 69
2 YNVTQAFGRRGPEQTQ YNVTQAFGRRGPEQTQ FNMVQAFGLRGPGDLQ 56
3 DQVILLNKHIDAYKTF DNVILLNKHIDAYKTF KWLELLEQNIDAYKTF 56
4 TGAIKLDDKDPNFKDQ HGAIKLDDKDPQFKDN SGAIKLDPKNPNYNKW 50
Spike
1 NEVAKNLNESLIDLQE NEVAKNLNESLIDLQE QQVVKALNESYIDLKE 63
2 ESLIDLQELGKYEQYI ESLIDLQELGKYEQYI ESYIDLKELGNYTYYN 63
3 CVLGQSKRVDFCGKGY CVLGQSKRVDFCGKGY CVKAQSKRSGFCGQGT 56
4 RDLICAQKFNGLTVLP RDLICAQKFNGLTVLP RDLICAQYVAGYKVLP 50
5 EAEVQIDRLITGRLQS EAEVQIDRLITGRLQS EQDAQIDRLINGRLTT 50
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It is again important to note that all the predicted B cell epitopes for E, N, M, and S were
found to be 100% conserved in the latest deposited 5000 SARS-CoV-2 sequences as well
as in the three variants (B.1.1.7, B.1.351, and P.1) of SARS-CoV-2 (Table 5, Supplementary
Figure S5).
Table 5. List of immunogenic and non-toxic T and B cell epitopes from E, N, M, and S proteins. The table shows sequences
of the shortlisted epitopes, their immunogenicity and toxicity score, and conservation (including level of conservation)
between seven HCoVs and the three closely related SARS-CoV-2, SARS-CoV, and MERS-CoV as well as in three variants of
SARS-CoV-2. The last column shows whether these epitopes have previously been experimentally validated or not.



















1 SLVKPSFYV 0.414 Non-toxin - 44 100 [58,59]
Membrane
1 SYFIASFRL 0.4821 Non-toxin 55 66 100 [59–61]
2 AGDSGFAAY 0.9095 Non-toxin - 44 100 [61,62]
Nucleocapsid
1 SPRWYFYYL 0.734 Non-toxin 44 77 100 [62,63]
2 QASSRSSSR 0.8294 Non-toxin - 66 100 [59]
3 VPINTNSSP 0.4439 Non-toxin - 66 88 [62]
Spike
1 DLLFNKVTL 0.68 Non-toxin - 77 100 [62,64,65]
2 NLNESLIDL 0.6827 Non-toxin - 77 100 [58,59,64]
3 VVNQNAQAL 0.4749 Non-toxin - 66 100 [64]
4 AYRFNGIGV 1.2995 Non-toxin - 55 100 [62,64,65]
5 VVFLHVTYV 1.5122 Non-toxin - 44 100 [62]


















1 YSFVSEETGTLIVN 0.4532 Non-Toxin - 50 100 [66]
2 YSFVSEETGTLI 0.5014 Non-Toxin - 42 100 [66]
Nucleocapsid
1 TASWFTALTQHGKEDL 0.4149 Non-Toxin - 69 100 -
2 YNVTQAFGRRGPEQTQ 0.4899 Non-Toxin - 56 100 -
3 TGAIKLDDKDPNFKDQ 1.8438 Non-Toxin - 50 100 -
Spike
1 ESLIDLQELGKYEQYI 0.6105 Non-Toxin - 63 100 -
3.4. Selection of Immunogenic Non-Toxic CD8+ T and Linear B Cell Epitopes for Design of
Multi-Subunit Vaccine
In the next step, the immunogenicity and toxicity profile of all the predicted epitopes
found to be conserved in the E, N, M, and S proteins of SARS-CoV-2 and other HCoVs was
evaluated. Among the CD8+ T cell epitopes, one out of two epitopes for E, two out of four
epitopes for M, three out of eight epitopes for N, and six out of fourteen epitopes for S were
predicted to be immunogenic and non-toxic, with the highest immunogenic score (1.5) for
the peptides of S, followed by M, N, and E (Table 5). From B cell epitopes, two out of two
epitopes for E, three out of four epitopes for N, and one of five epitopes for the S protein
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were predicted to be immunogenic and non-toxic, with the highest immunogenic score (1.8)
for the peptides of N, followed by S and E (Table 5). B cell epitope for M, however, was
predicted to be non-immunogenic. Therefore, the B cell epitope for M was not selected for
further analysis. A total of 18 (12 CD8+ T cell and 6 linear B cell) immunogenic, non-toxic,
and conserved epitopes were subsequently used to construct a multi-subunit vaccine.
3.5. Design and Assessment of the Multi-Subunit Vaccine
Physico-chemical assessment of the vaccine construct revealed the estimated half-life
of the vaccine to be 30 h in mammalian reticulocytes (in vitro), >20 h in yeast (in vivo), and
>10 h in Escherichia coli (in vivo). The instability index was predicted to be 33.06, classifying
the vaccine as stable. The aliphatic index and grand average of hydropathicity (GRAVY) of
the vaccine was found to be −0.250, making the construct hydrophilic and capacitating it
to interact better with the neighboring water molecules [37]. The molecular weight of the
construct was found to be 34,336.60 daltons. The solubility index of the vaccine construct,
based on Protein-Sol calculation, was found to be 0.34, indicating an acceptable solubility
profile for the vaccine. Allergenicity and immunogenicity prediction revealed the construct
to be a probable antigen (VaxiJen score 0.56) and non-allergen.
3.6. Secondary and Tertiary Structure of the Multiepitope Vaccine:
Secondary structure assessment of the vaccine construct showed that the construct
had 11 helices and 11 strands (Figure 3). The 3D structure of the vaccine was constructed
using both the Phyre2 and I-TASSER tools. The structure constructed using I-TASSER
had an overall low-quality score after refinement, and on a Ramachandran plot, only 88%
residues were in the favorable region (data not shown). To the contrary, the 3D structure
predicted by the Phyre2 tool after refinement (Figure 4A) exhibited a high confidence score,
ranging from 84–96% for most regions, and 66–74% for some regions. The Ramachandran
analysis of the structure showed that the predicted structure had 94.3% of the residues
in a highly preferred region, 4.5% in a preferred region, and only 1.1% residues in a non-
preferred/disallowed region (Figure 4B). The PROSA score of the structure predicted by
Phyre2 was −2.94, which lies in the acceptable range (Figure 4C). Overall, the assessment
of the different protein quality parameters indicates the structure predicted by Phyre2 to
be of high quality.
3.7. Molecular Docking Analysis of the Vaccine–TLR4 Complex
To reveal the binding modes and energies of the developed vaccine with human
TLR4, the molecular docking technique was utilized. All possible vaccine–TLR4 solutions
(exactly 1000 solutions) were first predicted using the PatchDock server [50]. The predicted
vaccine–TLR4 complex solutions were then refined, and the global binding energies were
rescored using the FireDock server [51,52]. The 3D representation of the predicted vaccine–
TLR4 complex structure is depicted in Figure 5, and the estimated global binding energy
and energy contributions for the top-ranked vaccine–TLR4 complex are listed in Table 6.
Interactions between the vaccine–TLR4 complex were resolved using LigPlot+ software.
The global binding energy estimates suggest that our vaccine construct formed a stable
complex with TLR4, with global binding energy of −47.76 kcal/mol(Table 6 and Figure 5A).
Assessment of the energy contributions revealed that attractive van der Waals (vdW) was
the dominant force in vaccine–TLR4 binding energy, with a value of −36.33 kcal/mol
(Table 6). Analysis of the protein–protein interaction suggested that the construct formed
multiple interactions with TLR4, especially with several residues of β-defensin (adjuvant
used in our construct, and a known agonist of TLR4 [46,47] were also found to interact
with TLR4 (Figure 5B).
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Figure 3. Secondary structure prediction of the vaccine construct. The color-coding of different regions is explained in
the legend within the figure. For secondary structure prediction, C, H, and E symbols indicate the coil, helix, and strand
regions, respectively.
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Figure 4. Predicted 3D structure of the vaccine and its quality assessment. (A) Predicted 3D structure of the vaccine (black)
showing T cell epitopes in red, while B cell epitopes in orange, (B) Ramachandran plot for the 3D structure of the vaccine
showing 97.8% of the residues in the favorable region, (C) ProSA z-score for the 3D structure of the vaccine, determined
using NMR spectroscopy (dark blue) and X-ray crystallography (light blue).
Table 6. Docking results of the developed vaccine with human toll-like receptor 4 (TLR4). The table shows global binding











Vaccine-TLR4 −47.76 −36.33 16.90 15.29 −0.42
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Figure 5. Molecular docking analysis between vaccine construct and TLR4. (A) Docked complex of the designed vaccine
with TLR4, (B) amino acid interaction between vaccine–TLR4 (vaccine construct: chain E; TLR4: chain A; C: Lymphocyte
antigen 96), resolved using LigPlot+ (DIMPLOT). Residues that are part of β-defensin found to interact with TLR4 are
highlighted in orange.
3.8. In Silico Simulation of the Immune Response against the Vaccine Construct
We performed in silico immune simulations to examine the potential of our vaccine
construct to elicit potent and durable B (including antibody response) and T cell responses.
Results from proteasomal processing showed that the proteasomal sites in the vaccine
are strategically located to release all 9-mer T cell epitopes and variable-length B cell
epitopes (Supplementary Figure S2). Results from the immune simulation showed that
the vaccine construct was predicted to elicit significant titers of IgG and IgM (Figure 6A),
significant effector and memory B-cell response (Figure 6B) as well as cytotoxic T cell and
interferon-gamma response (Figure 6C). Overall, the vaccine construct was predicted to be
stable, non-toxic and highly immunogenic, and capable of mounting a sustained protective
immune response.
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Figure 6. Simulated immune response after administration of the vaccine construct: The graphs show stimulation of (A) IgG,
IgM, and total antibody response, (B) Effector and memory B cell response, (C) Active and anergic CD8+ T cell response,
and (D) IFN-gamma and other cytokine responses after vaccine administration; (D) (insert): plot shows levels of danger
signal (positive or negative signals immune systems generate in response to ‘danger’ such as pathogens (Ramadan et al.,
2017)) together with leukocyte growth factor IL-2 over days.
4. Discussion
Using immunoinformatic tools, we have designed, constructed, evaluated, and as-
sessed the performance of a non-allergenic and antigenic chimeric multi-epitope vaccine
that combines T and B cell epitopes from conserved regions of the E, M, N, and S proteins
of seven human coronaviruses. The vaccine shows potential to elicit a strong response
against SARS-CoV-2 while also providing immune protection against emerging SARS-CoV-
2 variants and other HCoVs.
All of the currently available vaccines target the SARS-CoV-2 S protein, which is the
most antigenic, highly variable, and prone to mutations [19,20]. Due to the high substitu-
tion/mutation rate and rapid transmissions, new variants of SARS-CoV-2 have been con-
tinuously emerging globally, posing threats to circumvent the efficacy of current vaccines,
possibly leading to a novel-SARS-CoV-2-variant-assciated surge in transmissions [15]. In
fact, there have already been reports of the current vaccines losing effectiveness against the
emerging SARS-CoV-2 variants [21,22]. Variants of high concern, B.1.1.7 (VOC-202012/01)
identified in the U.K.; 501Y.V2 (B.1.351) identified in the South Africa; and P.1 (B.1.1.28.1)
identified in Brazil, all have more than 20 mutations in the S protein, raising the concern
that both natural infection-derived immunity as well as vaccine-derived immunity may
fail to confer protection against a SARS-CoV-2 variant (re)infection [15,21]. This hypothesis
has been partly supported by a recent study showing that the 501Y.V2 (B.1.351) variant
presents a complete immune escape from natural immunity [67]. Nonetheless, efforts to
design new vaccines or to improve the existing vaccines that can confer immunity against
SARS-CoV-2 and its variants are underway. In this regard, numerous in silico studies
have also been conducted to design multi-epitope vaccine candidates against SARS-CoV-2.
Vaccines 2021, 9, 702 21 of 27
However, most of these studies focused on epitopes from SARS-CoV-2 S protein as the
antigenic targets [37,68–71], while others included the N and M proteins [72,73].
The primary structure of the protein can provide information regarding mutations
and the conservation of residues, while the secondary structure, depicting the spatial
orientation, such as β-folds and α-helices, can give insights into how the protein will fold
into its final form. Finally, the tertiary structure depicts the three-dimensional orientation
of the protein in space [74]. The nature of the amino acids and protein folding can affect the
physio-chemical properties of the protein, such as solubility, stability and interaction with
other molecules, etc. [74]. The physico-chemical analyses revealed the molecular weight of
our vaccine, 34.34 kDa, indicating that it is an ideal vaccine candidate, as proteins with a
molecular weight less than 100 kDa are considered to be efficient vaccine candidates [70].
The instability index of our vaccine construct was shown to be 33.06, indicating that our
construct is stable, as proteins with an index greater than 40 are generally considered
unstable [38]. The vaccine construct was also found to be thermo-stable, with an aliphatic
index of 72.00. A high aliphatic index is an indication of a protein to be thermo-stable over
a wide temperature range [75]. The GRAVY index was predicted to be −0.250, reflecting
high solubility of the vaccine and its effective interaction with water molecules [76]. The
half-life of the vaccine was found to be 30 h in mammalian reticulocytes (in vitro), >20 h
in yeast (in vivo), and >10 h in Escherichia coli (in vivo). Vaccine candidates with similar
a half-life have been found to induce strong humoral and cellular responses in mice [77].
Finally, a refined and validated vaccine model showed that the designed vaccine is of high
quality, with >97% of residues in the favored region [78].
In our study, we analyzed all the structural proteins, E, N, M, and S, not only in
SARS-CoV-2 and its known variants, but also from six other human coronaviruses, and
selected highly conserved epitopes with the aim of designing an effective multi-subunit
vaccine that can be effective against SARS-CoV-2 and its variants and may also confer
cross-immunoprotection against other HCoVs. Yazdani et al. [79] conducted a similar
study using the E, N, M, and S proteins, however, this work investigated the conservation
of peptides for only SARS-CoV-2 and SARS-CoV. In addition, the final epitopes selected
in their study presented a lower antigenicity score (~0.7), while the epitopes we used in
our design exhibited a high immunogenicity score of 1.5 for CD8+ T epitopes residing in S
protein, and of 1.8 for linear B cell epitopes residing in the N protein. As our multi-subunit
vaccine contains peptides from multiple proteins which are 100% conserved in the B.1.1.7,
501Y.V2, and P.1 variants SARS-CoV-2, mutations that potentially reduce immunogenicity
are not likely to occur. The existence of cross-immune reactivity has been documented in
several studies [80–84]. It has been reported that the antigenic domains of the S and N
proteins are highly cross-reactive across coronaviruses [80,82,83], and it has been shown
that T cell immunity previously induced by circulating human alpha- and beta-HCoVs in
young adults is protective against severe clinical outcomes [81].
An ideal vaccine candidate, on the one hand, should be immunogenic/antigenic, and
should be able to elicit targeted humoral and cellular immune responses, while, on the
other hand, should also be non-toxic and non-allergenic [85], hence providing protection
against adverse effects. Vaccines using a complete agent (virus, for example) or large
proteins carry an increased chance of allergenic response due to the unnecessary antigenic
load introduced in the vaccine design [86]. This drawback is avoided in our construct,
as we used short immunogenic peptides that were predicted to be non-allergenic and
non-toxic. Moreover, the predicted conserved T and B cell epitopes used for our multi-
subunit vaccine can elicit cellular and humoral immune responses simultaneously, further
increasing the chance of triggering an efficient overall immune response. Additionally, our
vaccine was constructed with β-defensin as an adjuvant at the N-terminal, which allows
for a long-lasting immune response. β-defensin has been shown to be an efficient adjuvant
capable of enhancing the immunogenicity of candidate vaccines against viruses, including
MERS-CoV [14,87].
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In the immune simulation analyses, these properties were predicted for our vaccine
construct as well, showing that the vaccine may be able to elicit a sustained IgG, IgM, B-
and cytotoxic T-response, and interferon-gamma response for well over 300 days. The
activation/release of interferon-gamma is a hallmark of antiviral activity by T cells, as
this cytokine is capable of killing the virus-infected cells [88]. Similarly, the analysis of
the immunological response in individuals enrolled in phase 1/2 trial of the ChAdOx1
nCoV-19 vaccine showed that a single dose of the vaccine in adults was able to induce a
potent immune response, primarily composed of neutralization antibodies of IgG1 and
IgG3 subclasses, TH-1 response with interferon-γ, and tumor necrosis factor-α cytokine
secretion by CD4+ T cells as well as mono- and poly-functional and cytotoxic CD8+ T cells
up to 8 weeks after vaccination [89]. Similar results were observed for the Pfizer/BioNTech
and Moderna vaccines, where robust T cell response against spike protein of SARS-CoV-2
was observed in vaccinated individuals, which was more profound than the response
observed in convalescent patients [90]. Moreover, the CD8+ T cell epitopes in our vaccine
design were linked with the AYY linker that provides binding sites for the transporter
associated with antigen processing (TAP) to facilitate epitope presentation [91], while B
cell epitopes were linked with the glycine rich GPGPG linker, which gives the vaccine
structural flexibility, prevents junctional epitope formation, and helps immune processing
and epitope presentation [91].
Lastly, in molecular docking studies, using TLR4 showed that our vaccine construct,
and especially several of β-defensin residues, a known TLR4 agonist [46,47] used as an
adjuvant in our vaccine, can form stable complexes with the TLR4. TLR-4 is capable of
recognizing various exogenous and endogenous ligands such as viral protein, lipopolysac-
charide, heat shock proteins, β-defensin, etc., which leads to dendritic cell maturation and
up-regulation of costimulatory molecules, resulting in a type 1 polarized adaptive immune
response [46,47]. Recently, Zhao et al. showed that SARS-CoV-2 is able to activate TLR4 to
activate an anti-bacterial like immune response [92]. Similarly, other in silico studies have
shown that the ability of a vaccine construct to form stable complexes with these TLRs may
lead to the induction of antiviral immunity [37,93].
5. Conclusions
Multi-epitope vaccines designed using immune-informatics have been widely studied
against viruses as well as against cancer [94–97]. Some of these vaccines have shown
promising results in vivo, while some entered clinical trials [98–102]. Analyzing a vaccine
construct in silico before proceeding to in vitro evaluations and clinical trials is an efficient
way to determine the vaccine’s potential with confidence, economizing on time, effort,
and money. Here we present in silico analyses of a multi-subunit vaccine design that,
from multiple perspectives, shows potential to elicit a strong immune-protective response
against SARS-CoV-2 and its emerging variants, while carrying minimal risk for causing
adverse effects.
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